Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. (Q52587655)
Jump to navigation
Jump to search
scientific article published on 16 April 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. |
scientific article published on 16 April 2018 |
Statements
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. (English)
Carla M Canuso
Jaskaran B Singh
Maggie Fedgchin
Larry Alphs
Rosanne Lane
Pilar Lim
Christine Pinter
David Hough
Gerard Sanacora
Husseini Manji
Wayne C Drevets
16 April 2018
appiajp201817060720